Two of India’s largest pharmaceutical companies have initiated product recalls in the United States following observations flagged by the U.S. Food and Drug Administration, drawing attention to the growing regulatory pressure on global generic drug manufacturers. The recalls, described as precautionary and limited in scope, involve specific batches distributed in the U.S. market. While neither company reported widespread safety incidents, the action underscores the strict compliance environment governing pharmaceutical exports.
